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Abstract: We aim to estimate the diagnostic performances of anterior gradient homolog-2 
(AGR2)  and  Leucine-rich  repeat-containing-G-protein-coupled  receptor  5  (LGR5)  in 
peripheral blood (PB) as mRNA biomarkers in colorectal cancer (CRC) and to explore 
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their prognostic significance. Real-time PCR was used to analyze AGR2 and LGR5 in 54 
stages I-IV CRC patients and 19 controls. Both mRNAs were significantly increased in PB 
from  CRC  patients  compared  to  controls.  The  area  under  the  receiver-operating 
characteristic curves were 0.722 (p = 0.006), 0.376 (p = 0.123) and 0.767 (p = 0.001) for 
AGR2, LGR5 and combined AGR2/LGR5, respectively. The AGR2/LGR5 assay resulted in 
67.4% sensitivity and 94.7% specificity. AGR2 correlated with pT3–pT4 and high-grade 
tumors. LGR5 correlated with metastasis, R2 resections and high-grade. The progression-free 
survival (PFS) of patients with high AGR2 was reduced (p = 0.037; HR, 2.32), also in the 
stage I-III subgroup (p = 0.046). LGR5 indicated a poor prognosis regarding both PFS  
(p = 0.007; HR, 1.013) and overall survival (p = 0.045; HR, 1.01). High AGR2/LGR5 was 
associated  with  poor  PFS  (p  =  0.014;  HR,  2.8)  by  multivariate  analysis.  Our  findings 
indicate  that  the  assessment  of  AGR2  and  LGR5  in  PB  might  reflect  the  presence  of 
circulating tumor cells (CTC) and stem cell like CTC in CRC. Increased AGR2 and LGR5 
are associated with poor outcomes. 
Keywords: colorectal cancer; real-time PCR; circulating tumor cells; prognostic markers; 
stem cells; anterior gradient homolog-2; leucine-rich repeat-containing G-protein-coupled 
receptor 5 
 
1. Introduction 
Colorectal cancer (CRC) is one of the leading causes of cancer-associated morbidity and mortality 
across the world. The predicted number of deaths in 2011 in the European Union due to CRC was 
162,026 [1]. The stage at diagnosis and the possibilities for curative surgery remain the most important 
prognostic factors.  
The development of blood-borne metastasis is ultimately responsible for most CRC-related deaths. 
Sensitive methods to detect circulating tumor cells (CTC) could serve as prognostic or predictive tools 
to identify patients at a high risk of disease progression who could be selected for additional treatment [2].  
CTC are identified mainly by using antibodies against epithelial antigens or molecular approaches. 
The PCR amplification of tissue- or tumor-specific mRNA is commonly used to detect circulating or 
occult  metastatic  cells.  Systematic  reviews,  meta-analyses  and  prospective  studies  [3–7]  provide 
coherent  evidence  that  the  molecular  detection  of  CTC  in  the  peripheral  blood  (PB)  is  of  strong 
prognostic significance in patients with CRC.  
Our study aimed to evaluate promising CRC-specific mRNAs for multi marker detection of CTC in 
PB. We previously [8,9] identified anterior gradient homolog-2 (AGR2) and plakophilin-3 as potential 
CTC markers in gastrointestinal cancer through an in silico profile of gene expression and quantitative 
real-time reverse-transcription PCR (qRT-PCR). Moreover, AGR2 has been included in the molecular 
signature that defined CTC in metastatic breast, prostate and colorectal cancers [10,11].  
AGR2  encodes  a  17  kDa  secreted  protein,  homologue  of  the  Xenopus  cement  gland  gene  
XAG-2  [12].  Although  its  functions  in  humans are  poorly  understood,  recent  reports  indicate  that Int. J. Mol. Sci. 2012, 13  4369 
 
 
AGR2 can induce cellular transformation and tumor growth, promote cell survival through inhibition 
of p53, enhance tumor cell adhesion to the substratum and enhance cell migration [13–15]. 
Recent  data [2,10,11,16,17] suggest  that CTC  encompass a heterogeneous  cell population  with 
different  tumorigenic  capabilities  and  include  cells  characterized  by  an  epithelial-mesenchymal 
plasticity (EMP) with transient loss of epithelial markers. In that sense, the use of different mRNA 
biomarkers will yield better results in the identification of CTC and rare cell subsets of biological 
relevance.  Thus,  it  has  been  hypothesized  that  only  CTC  with  tumor-initiating  properties  will 
eventually complete the metastatic cascade and will develop clinically relevant metastases [18]. 
The  leucine-rich  repeat-containing  G-protein-coupled  receptor  5  (LGR5)  also  known  as  
G-protein-coupled receptor 49 (GPR49), has been recently reported as a marker for stem cells (SC) in 
the small intestine and colon [19]. Recently [20,21] it was shown that the LGR5 gene and protein were 
markedly  over  expressed  in  the  majority  of  advanced  CRCs  and  in  CRC  cell  lines  derived  from 
metastatic tumors. Moreover, high LGR5 expression has been associated with poor progression-free 
survival for CRC patients [22]. 
Thus, we hypothesized that LGR5 mRNA expression in PB of CRC patients could indicate the 
presence of circulating tumor cells with stem cell properties.  
The  primary  aims  of  our  study  were  to  estimate  prospectively  the  diagnostic  accuracy  and 
usefulness of AGR2 mRNA in PB as a surrogate biomarker of CTC and to explore its prognostic 
significance. Additionally, the blood expression of the intestinal stem-cell (ISC) marker LGR5 was 
evaluated for correlations with AGR2 and clinical parameters. Our findings revealed that molecular 
assessment of AGR2 and LGR5 can serve as a marker of CTC and ISC-like CTC in CRC patients, 
which underscores their potential clinical relevance as predictors of disease outcome. 
2. Results and Discussion 
2.1. Results 
2.1.1. Patients and Clinical Data 
Starting in July 2004, 54 patients with histological proven CRC and 19 controls were consecutively 
recruited for this study. This sample size allowed us to estimate an expected area under the ROC curve 
of 0.70 with a standard error of 0.065. Ninety per cent of the subjects were included within the first 
two years. The clinical characteristics of the patients are shown in Table 1. 
Table 1. Patient baseline and clinical characteristics. 
  Mean (SD)  Range 
Age (years)  62.7 (9.6)  31–80 
  N  % 
<60 years  20  37.0 
≥60 years  34  63.0 Int. J. Mol. Sci. 2012, 13  4370 
 
 
Table 1. Cont. 
Gender     
Female  21  38.9 
Male  33  61.1 
Stage     
I-II  6  11.1 
III  12  22.2 
IV  36  66.7 
pT     
pT1-pT2  6  14.1 
pT3  36  66.7 
pT4  8  14.8 
pTx  4  7.4 
pN     
pN0  13  24.1 
pN1  26  48.1 
pN2  11  20.4 
pNx  4  7.4 
M     
M0  18  33.3 
M1  36  66.7 
Residual disease status     
R0-R1  16  29.6 
R2  38  70.4 
Number of Metastatic Sites     
0  18  33.3 
1  25  46.3 
≥2  11  20.4 
Location of Metastasis     
None  18  33.3 
Liver Only  23  42.6 
Liver and Other  11  20.4 
Non-liver Metastasis  2  3.7 
Grade     
Low Grade  10  18.5 
High Grade  44  81.5 
Vascular/Perineural Invasion     
Unknown  6  11.1 
No  24  44.4 
Yes  24  44.4 
The mean age was 62.2 years (SEM 1.84; median, 62 years; range, 43 to 74 years) in the control 
group and 62.7 (SEM 1.30; median, 62.5; range, 31 to 80 years) in the patient group (t test, p = 0.847). 
The ratio of males to females was similar in the controls (men 63.2%) and the patients (men 61%)  
(χ
2 test, p = 0.875). Int. J. Mol. Sci. 2012, 13  4371 
 
 
PB samples were obtained after R0 or R1 surgery in 16 patients. In 38 patients, blood samples were 
obtained before neo-adjuvant chemotherapy or in the presence of active metastatic disease, both of 
which were categorized as R2. In patients with node-negative disease and R0 resection, the mean 
number of lymph nodes analyzed was 12.8 (SEM 2.7; range 7–21). 
Patients with metastatic CRC (n = 38) were grouped into high- (19.4%), intermediate- (36.1%) and 
low-risk groups (44.4%) using performance status, number of tumor sites, alkaline phosphatase and 
white  blood  cell  count,  as  suggested  by  Kö hne  et  al.  [23]  Median  overall  survival  (OS)  and 
progression-free survival (PFS) were 98 and 39 weeks, 56 and 26 weeks, and 59 and 14 weeks for the 
low-,  intermediate-  and  high-risk  groups,  respectively.  The  median  OS  tended  to  be  higher  
(log-rank  p  =  0.061)  in  the  low-risk  group  (98  weeks;  95%  CI,  43.1  to  152.9)  compared  to  the 
combined intermediate/high-risk group (56 weeks; 95% CI, 47.2 to 64.8). 
All  patients  were  followed  up  until  death  or  the  end  of  the  study.  Disease  progression  events 
occurred  in  39  patients  (72.2%).  There  were  three  relapses  among  stage  I–III  patients  and  36 
progressions of metastatic disease. The median PFS was 44 weeks (95% CI, 24.8 to 63.2 weeks). The 
median OS was 132 weeks (95% CI, 84.4–179.6 weeks), and 34 patients (63%) died of advanced 
disease. The mean (SEM) follow-up time for the patients still alive at the time of the analysis was  
232 (17.8) weeks (median, 232.5 weeks; range, 67 to 335 weeks). 
2.1.2. Expression of AGR2 and LGR5 mRNA Transcripts in Blood Samples 
AGR2 mRNA was quantified in 62 blood samples (84.9%), including 43 samples obtained from 
patients with CRC and 19 from controls. The LGR5 mRNA level was quantified in 67 blood samples 
(90.5%), 48 from CRC patients and 19 from controls. mRNA was insufficient or its quality was inadequate 
for qRT-PCR in 11 (15.1%) and 6 (8.2%) patients‘ samples for AGR2 and LGR5 respectively. 
The mean relative AGR2 mRNA expression was 29.1 (SEM 28.2; median 0.77; range, 0.21 to 536.7) 
in controls and 418.57 (SEM 84.4; median 191.2; range, 0.05 to 1989.5) in cancer patients (t test, p < 0.001). 
Likewise, the AGR2 level was significantly increased (ANOVA, p = 0.007) in patients with stage IV 
CRC (mean 492.6; SEM 114) compared with stage I to III patients (mean 305.4; SEM 122.5) and  
non-cancer controls (mean 29.1; SEM 28.2).  
The mean LGR5 mRNA level was 0.21 (SEM 0.03; median 0.18; range, 0 to 0.4) in controls and 
11.6 (SEM 4.9; median 0.08; range, 0.01 to 146.9) in patients (t test, p = 0.026). The LGR5 level was 
significantly increased (ANOVA, p = 0.038) in patients with stage IV CRC (mean 18.40; SEM 7.70) 
compared with stage I to III patients (mean 0.20; SEM 0.06) and non-cancer controls (mean 0.21; SEM 0.03). 
There  was  no  correlation  between  AGR2  and  LGR5  blood  levels  in  the  patients  group  (Pearson 
correlation coefficient −0.009; p = 0.952). 
ROC curves of circulating mRNAs were constructed in order to be able to discriminate different 
groups (Figure 1). Int. J. Mol. Sci. 2012, 13  4372 
 
 
Figure 1. AGR2 and LGR5 ROC curves. mRNA relative levels were quantified in blood 
obtained from  patients  with colorectal cancer and from  controls. Area under the curve 
(AUC), 95% confidence interval and p-values are shown.  
 
Comparing  the  relative  AGR2  levels  in  patients  and  controls,  the  AUC  was  0.722  (95%  CI,  
0.594–0.849; p = 0.006). According to the ROC curve, a relative level for AGR2 mRNA in the blood of 
1.65 was defined as the optimal cutoff value (Youden index) for differentiating patients with CRC 
from the controls. With this cutoff value for AGR2, the sensitivity and specificity of 62.8% (95% CI, 
46.7 to 76.6) and 94.7% (95% CI, 71.9 to 99.7) respectively, were achieved. At this threshold value, 
AGR2 positivity was associated with CRC diagnostic (p < 0.001).  
The ROC curve for LGR5 showed an AUC of 0.376 (95% CI, 0.233–0.520; p = 0.123). A relative blood 
level of 0.39 was defined as the optimal cutoff point for LGR5. With this cutoff value, the sensitivity 
and specificity for the LGR5 mRNA assay were 18.8% (95% CI, 9.4 to 33.10) and 100% (95% CI,  
79.1  to  99.5)  respectively.  At  this  cutoff  value,  LGR5  positivity  tended  to  associate  with  CRC 
diagnostic (p = 0.052).  
In CRC patients, relative expression values for AGR2 and/or LGR5 in blood above these cutoff 
points, defined as the Youden index, were found in 16.7% of stage I–II, in 72.7% of stage III and in 
76.9% of stage IV patients (χ
2 test; p = 0.016).  
AGR2  and  LGR5  markers  were  analyzed  in  combination  by  logistic  regression.  The  predicted 
probabilities of diagnosis generated a ‗combination marker‘ ROC curve. The combination (AGR2/LGR5) 
had an AUC-ROC  = 0.767 (95% CI, 0.648–0.886;  p  = 0.001) which  was  slightly improved [24] 
compared to AGR2 alone (p = 0.25). The sensitivity and specificity of the combination were 67.4% 
(95% CI, 51.3 to 80.5) and 94.7% (95% CI, 71.9 to 99.7) respectively (Figure 1). Int. J. Mol. Sci. 2012, 13  4373 
 
 
2.1.3. Clinic Pathological Characteristics and mRNA Markers in Blood 
The clinical and pathological characteristics and the AGR2 and LGR5 mRNA expression in blood 
from cancer patients are shown in Table 2. 
Table  2.  Distribution  of  clinical  and  pathological  parameters  and  levels  of  AGR2  and 
LGR5 mRNA in the blood.  
Parameter  AGR2    LGR5   
  Mean  SEM  p  Mean  SEM  p 
Age (y)      0.459      0.128 
<60  497.0  142.2    22.5  10.0   
≥60  367.3  105.1    5.0  5.0   
Gender      0.075      0.203 
Male  291.1  87.9    5.8  3.9   
Female  633.7  161.5    22.1  11.7   
Stage      0.137 *      0.204 * 
I-II  1.1  0.2    0.3  0.05   
III  471.3  171.2    0.1  0.08   
IV  492.6  113.8    18.4  7.7   
pT      0.002 
a      0.915 
pT1-T2  82.1  57.5    10.7  10.5   
pT3-T4  453.7  92.4    12.5  5.8   
pN      0.063 *      0.309 * 
Node Negative  306.9  162.3    0.26  0.05   
pN1  311.7  80.4    13.1  7.01   
pN2  795.2  266.3    23.9  16.4   
M      0.283      0.024 
a 
M0  305.4  122.5    0.18  0.06   
M1  492.6  113.8    18.4  7.7   
R Status      0.671      0.024 
a 
R0-R1  363.2  156.1    0.13  0.03   
R2  442.6  101.7    40.3  7.01   
Number of Metastatic sites      0.373 *      0.159 * 
0  305.4  122.5    0.18  0.06   
1  407.7  145.0    21.5  10.6   
≥2  628.4  184.7    12.3  9.3   
Grade      0.023 
a      0.024 
a 
Low grade  183.0  71.9    0.1  0.04   
High grade  480.9  102.8    14.6  6.1   
Vascular/Perineural Invasion      0.751      0.269 
No  385.8  100.6    6.6  6.5   
Yes  441.2  146.1    18.6  8.5   
AGR2 and LGR5, mean relative expression levels, arbitrary units; SEM: standard error of the median, t-test;  
* ANOVA; 
a p values of less than 0.05. Int. J. Mol. Sci. 2012, 13  4374 
 
 
A significant higher relative level of AGR2 blood expression was found in pT3-T4 tumors (p = 0.002) 
and high-grade lesions (p = 0.023). There was a tendency (p = 0.063) to higher AGR2 levels associated 
with lymph node metastasis. Increased LGR5 expression was found in patients (Table 2) with stage IV 
(p = 0.024), R2 resections (p = 0.024) or high-grade tumors (p = 0.024). 
Carcinoembryonic  antigen  (CEA)  and  carbohydrate  antigen  19.9  (CA  19.9)  serum  levels  were 
increased above the upper limits of normal in 46.3% and 38.9% of the patients, respectively. There 
were  no  correlations  between  AGR2  or  LGR5  mRNA  levels  with  CEA  or  CA  19.9  in  serum  
(Pearson −0.172, −0.155, 0.021 and −0.063 respectively). 
To explore the possible influence of recent surgery on the circulation of tumor cells, we analyzed 
AGR2 and LGR5 levels according to the time interval from operation and blood sampling. The mean 
time from surgery to blood sampling for mRNA quantification was 52.5 weeks (SEM 8.7 weeks; 
median,  18  weeks;  range,  1  to  202  weeks).  The  25th  percentile  was  6.75  weeks.  There  was  no 
significant difference in AGR2 and LGR5 levels between time intervals (<6.75 or ≥6.75 weeks) from the 
last surgery.  
In the group of patients with stage IV disease, AGR2 and LGR5 were analyzed according to the 
prognostic subgroups defined as described previously [19]. The mean (SEM) relative AGR2 levels 
were  443.1  (229.6)  and  518.8  (129.9)  for  low-  and  combined  intermediate/high-risk  groups, 
respectively (t test, p = 0.759). The median (SEM) relative LGR5 levels were 15.5 (11.7) and 20.6 (10.4) 
for low- and combined intermediate/high-risk groups, respectively (t test, p = 0.746).  
2.1.4. Prognostic Significance of AGR2 and LGR5 in Blood  
To  analyze  the  relationships  between  biomarker  expression  and  outcomes  (PFS  and  OS)  we 
estimated the hazard ratios associated with mRNA levels as continuous variables using Cox regression 
models [25]. There was a trend for a high risk of disease progression associated with increased AGR2 
relative blood expression (HR 1.0; 95% CI, 1.0 to 1.001; p = 0.093). There was no association with the 
risk of death (HR 1.0; 95% CI, 0.999 to 1.001; p = 0.913). However, in stage I to III patients, the risk 
of  disease  progression  was  higher  with  increasing  AGR2  level  (HR  1.002;  95%  CI,  1  to  1.004;  
p = 0.046).  
Increasing relative blood expression of LGR5 mRNA as a continuous variable was associated with a 
higher risk of disease progression (HR 1.013; 95% CI, 1.004 to 1.023; p = 0.007). The risk of death 
was also higher with increasing levels for LGR5 mRNA in the blood (HR 1.01; 95% CI, 1 to 1.020;  
p = 0.045). 
In addition, in order to generate survival curves, we converted continuous mRNAs expression levels 
measured on qRT-PCR to a dichotomous variable, using the mean levels of expression in the patients 
group as a threshold. Kaplan-Meier curves for patients categorized according to  AGR2 and LGR5 
mRNA expression in blood are shown (Figures 2–4). 
The median PFS for the group with high AGR2 blood expression were 33 weeks (95% CI, 11 to 55) 
compared with 86 weeks (95% CI, 0 to 305.1) in the group with low AGR2 (log-rank test, p = 0.033). 
Patients with high AGR2 showed worse OS (median 97 weeks; 95% CI, 0 to 262.9) compared with 
those with low AGR2 expression (median 192 weeks; 95% CI, 56.6 to 327.4) although this difference 
was not statistically significant (log-rank test, p = 0.6) (Figure 2). Int. J. Mol. Sci. 2012, 13  4375 
 
 
Figure 2. AGR2 and survival analysis. Kaplan-Meier plots of (a) progression-free survival 
(PFS)  and  (b)  overall  survival  (OS)  in  colorectal  cancer  patients  according  to  AGR2 
mRNA expression in blood. Relative quantification of AGR2 mRNA was calculated by the 
2
−Ct method using HPRT as a reference gene. Continuous mRNA levels were converted 
to a dichotomous variable using the mean levels of expression as a threshold. p estimates 
by  log-rank  test.  Hazard  ratios  (HR)  were  modeled  using  Cox  proportional  hazard 
regression analysis. 
 
(a) 
 
(b) 
Analysis of the patients‘ outcome according to LGR5 blood expression revealed that the high LGR5 
group exhibited significantly worse PFS (median 22 weeks; 95% CI, 0 to 48.4) compared with patients Int. J. Mol. Sci. 2012, 13  4376 
 
 
in  the  low  LGR5  group  (median  55  weeks;  95%  CI,  5.1  to  104.9)  (p  =  0.013).  Although  
non-significant, there was a trend (p = 0.061) for a better OS in the group of patients with low LGR5 
(median 179 weeks; 95% CI, 74.9 to 283.1) compared with the group with increased LGR5 blood 
levels (median 61 weeks; 95% CI, 28.6 to 93.4) (Figure 3). 
Figure 3. LGR5 and survival analysis. Kaplan-Meier plots of (a) progression-free survival 
(PFS) and (b) overall survival (OS) in colorectal cancer patients according to LGR5 mRNA 
expression in blood. Relative quantification of LGR5 mRNA was calculated by the 2
−Ct 
method using HPRT as a reference gene. Continuous mRNA levels were converted to a 
dichotomous variable using the mean levels of expression as a threshold. p estimates by log-rank 
test. Hazard ratios (HR) were modeled using Cox proportional hazard regression analysis. 
  
(a) 
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High mRNA in PB (combined AGR2 and/or LGR5 transcript above the threshold cutoff) was found 
in 0, 36.4% and 53.8% of stage I–II, III and IV patients, respectively (χ
2 test; p = 0.05). 
Patients were divided into favorable mRNA profile (both AGR2 and LGR5 below the mean) and 
unfavorable mRNA profile (AGR2 and/or LGR5 above the mean). At the time of analysis, the mean 
and the median PFS in the favorable group were 190.8 weeks (95% CI, 131.2 to 250.4 weeks) and not 
reached in the unfavorable group. The mean and the median PFS were 54.7 weeks (95% CI, 21.2 to 
88.1 weeks) and 32 weeks (95% CI, 17.5 to 46.6 weeks) in the unfavorable mRNA profile group  
(log-rank test p = 0.002) (Figure 4). 
Figure  4.  Combined  AGR2/LGR5  and  survival  analysis.  Kaplan-Meier  plots  of  
(a)  progression-free  survival  (PFS)  and  (b)  overall  survival  (OS)  in  colorectal  cancer 
patients  according  to  combined  AGR2/LGR5  mRNA  profile  in  blood.  Relative 
quantification of mRNA was calculated by the 2
−Ct method using HPRT as a reference 
gene. Patients were divided into favorable mRNA profile (both AGR2 and LGR5 below the 
mean) and unfavorable mRNA profile (AGR2 and/or LGR5 above the mean). p estimates 
by  log-rank  test.  Hazard  ratios  (HR)  were  modeled  using  Cox  proportional  hazard 
regression analysis.  
 
(a) 
 
(b) Int. J. Mol. Sci. 2012, 13  4378 
 
 
Multivariate Cox regression analyses were performed to determine whether high mRNA in blood 
were independently statistically predictive of PFS or OS (Table 3). 
Table  3.  Progression-free  survival  and  overall  survival  in  relation  to  clinic  and 
pathological characteristics and blood AGR2/LGR5 mRNA: Multivariate Cox proportional 
hazard analysis.  
    Wald  Hazard Ratio  95% CI  p 
Progression free survival         
Depth of invasion  pT1-2/pT3/pT4  1.042  1.430  0.720  2.841  0.307 
Lymph Nodes  Negative/Positive  0.834  1.714  0.539  5.445  0.361 
Residual disease  R0-1/R2  8.047  5.824  1.724  19.68  0.005 
AGR2/LGR5  Negative/Positive  6.025  2.803  1.231  6.385  0.014 
Overall survival           
Depth of invasion  pT1-2/pT3/pT4  0.741  1.443  0.626  3.322  0.389 
Lymph Nodes  Negative/Positive  0.020  1.085  0.348  3.384  0.888 
Residual disease  R0-1/R2  7.041  7.338  1.683  31.99  0.008 
AGR2/LGR5  Negative/Positive  1.158  1.594  0.682  3.724  0.282 
AGR2/LGR5 negative in blood indicate both mRNA markers below the mean; a positive result indicates 
AGR2 and/or LGR5 above the mean. 
In testing for the independent prognostic significance of high AGR2/LGR5 expression in a model 
with pT depth of invasion, lymph node involvement and residual disease (R resection status), the  
R status (HR of recurrence, 5.8; 95% CI, 1.7 to 19.7; p = 0.005) and the high mRNA blood expression 
(HR, 2.8; 95% CI, 1.2 to 6.4; p = 0.014) remained associated with PFS (Table 3). In this model, the 
only  factor  that  retained  independent  prognostic  significance  for  OS  was  R2-residual  disease  
(HR of death, 7.338; 95% CI, 1.683 to 31.985; p = 0.008). 
2.2. Discussion 
Highly  sensitive  detection  of  CTC  and  detailed  molecular  characterization  of  rare  cancer  cell 
subpopulations may not only provide insights into the biology of early metastatic spreading, but these 
tools can also potentially indicate substantial predictive or prognostic information. PCR amplification 
of tumor mRNA is a powerful analytical tool for surrogate detection and characterization of CTC. 
Real-time RT-PCR allows for quantification of the tumor cell load in the PB and, at least theoretically, 
the  determination  of  cutoff  values  of  mRNA  expression  of  clinical  relevance  in  cancer  patients. 
However,  the  sensitivity  and  specificity  of  this  approach  both  depend  on  the  expression  level  of 
candidate biomarkers in tumor cells as well as their background expression in the blood [26,27].  
Evidence is rapidly accumulating that cancers are composed of heterogeneous populations of cells. 
Thus, one would predict that CTC might be enriched in cancer cells that express those biomarkers 
indicating the greatest invasive and metastatic capacity, including cancer stem cells (CSC) markers. 
Hence, the selection of appropriate target mRNAs that may be useful for clinical detection of CTC and 
CSC remains an important outstanding issue. 
The  current  study  was  intended  to  assess  the  diagnostic  performance  of  quantitative  RT-PCR 
detection of AGR2 in the blood as a surrogate marker of CTC. We then hypothesized that a marker Int. J. Mol. Sci. 2012, 13  4379 
 
 
indicative of the phenotype of colonic stem cells, such as  LGR5, would improve the detection of 
biologically and clinically relevant CTC.  
We found that AGR2 mRNA was significantly elevated in the blood of patients with CRC compared 
to controls. ROC analysis suggested that at 94.7% specificity, AGR2 achieved 62.8% sensitivity in 
distinguishing CRC blood samples from the control group. Furthermore, in CRC patients, blood AGR2 
mRNA levels correlated with different pathological prognostic factors, including pT3–pT4 depth of 
invasion and high-grade tumors.  
These results are in line with the current evidence indicating that AGR2 can promote cancer growth, 
cell survival, migration and anchorage-independent growth and cellular transformation [14,28]. In the 
clinical setting, AGR2 protein expression in the primary tumor is an independent prognostic indicator 
of poor outcome in patients with breast [29] and prostate adenocarcinomas [30], and one recent study 
showed that increased AGR2 protein in plasma is associated with ovarian cancer [31].  
However, to the best of our knowledge, no comprehensive report has been published about the 
potential prognostic relevance of AGR2 in colorectal cancer. Our findings indicate for the first time 
that the quantitative assessment of AGR2 mRNA in blood might indicate a poor patient outcome in 
CRC. Remarkably, in stage I to III patients, the risk of disease progression was higher with increasing 
levels of AGR2 in the blood. Likewise, in CRC patients with high AGR2 blood expression, the PFS 
was significantly reduced, and there was a numerical but non-significant inferior OS. 
A recent study [32] demonstrates that AGR2 induces the expression of the growth-promoting EGFR 
ligand  amphiregulin  in  human  adenocarcinomas.  This  effect  is  mechanistically  mediated  through  
Yes-associated  protein  (YAP1)  dephosphorylation.  Interestingly,  YAP1  is  also  implicated  in  the 
regulation  of  stem  cell  division  through  the  repression  of  the  Hippo  pathway.  These  data  and  a 
previous report [14] show that proliferating and non-proliferating ISCs, as well as transit-amplifying 
cells from a secretory lineage express AGR2 and suggest additional mechanisms for oncogenic actions 
for AGR2.  
We next explored the expression of the ISC marker LGR5 in the blood of our cohort of controls and 
CRC patients. We found that LGR5 mRNA was significantly elevated in the blood of patients with 
colorectal carcinoma compared to controls. However, mean levels of LGR5 mRNA were similar in 
controls and early stage CRC patients. Nevertheless, there was a significant increase of LGR5 in blood 
obtained from metastatic CRC patients. When a cutoff point was defined based on the ROC curve, the 
LGR5 assay achieved only 18.8% sensitivity but 100% specificity in distinguishing CRC and control 
blood  samples.  Conversely,  LGR5  mRNA  in  the  blood  showed  a  significant  correlation  with  
high-grade tumors, metastatic disease and R2 resections.  Likewise,  LGR5 expression in the blood 
showed a prognostic value regarding both PFS and OS in CRC patients, as suggested by the Cox 
regression and Kaplan-Meier analysis. In that sense, our results suggested that LGR5 is expressed only 
in  a  rare  subset  of  CTC  possibly  including  cancer  stem-like  cells.  We  could  speculate  that  these 
circulating LGR5-expressing cells might contribute to cancer progression and therapeutic response.  
The clinical and biological significances of LGR5 expressing-cells in CRC are poorly understood.  
A primary tumor profile  that encompasses known ISC markers, such as  LGR5, has been strongly 
associated both  with  CRC stages and the occurrence of tumor relapse and metastasis [33].  LGR5 
protein expression had been associated with a poor PFS in CRC patients [22]. In contrast, in a recent Int. J. Mol. Sci. 2012, 13  4380 
 
 
report [34] a gene signature defined by methylation silencing of the Wnt-driven ISC marker genes, 
including LGR5, in CRC tumors was associated with a poor prognosis.  
A  number  of  proposed  CSC  markers,  such  as  CD44  and  CD133,  have  been  explored  in  CTC 
detection. Recently, Iinuma H. et al. [7] demonstrated in patients with Dukes‘ stage B and C CRC that 
the detection of CEA/Cytokeratins (CK) 19/20/CD133 mRNA in blood was useful for determining 
which  patients  were  at  high  risk  for  recurrence  and  poor  prognosis.  However,  in  the  CD133  
single-marker analysis, no significant differences in OS and PFS were found [7]. In metastatic CRC, 
the transcriptional amount of CD133 in blood before resection of hepatic metastases resulted in a high 
risk of dying of recurrence after apparently curative liver surgery [35]. Nonetheless, CD133 and other 
putative markers for CRC stem cells such as CD44 are also expressed in a variety of cells including 
hematopoietic and/or endothelial cells (reviewed Hundt, S. in [27]), a factor that could diminish their 
specificity. The expression patterns of LRG5 and colon differentiation markers such as cytokeratin−20 
are  mutually  exclusive  [33]  are  of  special  interest  for  CTC  detection.  These  facts  strengthen  the 
relevance  of  non-CK  mRNA  biomarkers  for  the  detection  of  the  most  aggressive  and  specific 
subpopulations of CTC in CRC patients. 
CTC  in  gastrointestinal  cancer  patients  are  increasingly  detected  when  blood  is  obtained  
per-  or  intra-operatively  [36].  However,  the  postoperative  sampling  time  might  reflect  the  most 
relevant CTC status [4,37]. In our study, blood samples were obtained several weeks after surgery. In 
order to explore the possible influence of recent surgery on the circulation of tumor cells, AGR2 and 
LGR5  levels  were  analyzed  according  to  time  intervals  between  surgery  and  blood  sampling; 
conversely, no significant differences in biomarker mRNA levels between time intervals were found.  
From a clinical perspective, assessment of baseline prognostic factors and CTC detection rates may 
be of interest. In previous studies [38,39] including patients with metastatic CRC, the number of CTC 
detected using the Cell Search System was associated with high LDH level, liver metastasis and poorer 
performance  status.  Hence,  we  performed  an  exploratory  analysis  in  the  subset  of  stage  IV  CRC 
patients,  which  showed  no  association  between  a  positive  mRNA  result  and  baseline  clinical 
prognostic subgroups categorized according to performance status, white blood cell count, alkaline 
phosphatase  and  number  of  metastatic  sites.  In  addition,  levels  of  AGR2  and  LGR5  were  not 
significantly different either.  
The  combined  AGR2  and  LGR5  assay  resulted  in  an  increased  sensitivity  (67.4%;  
AUC-ROC = 0.767; p = 0.001) to separate cancer patients and controls. Remarkably, and in spite of the 
limited number of patients, Cox multivariate analysis demonstrated that AGR2/LGR5 mRNA detection 
was  a  significant  prognostic  factor  for  PFS  (HR,  2.8;  95%  CI,  1.2  to  6.4;  p  =  0.014).  Thus,  the 
transcriptional amount of AGR2/LGR5 in the PB defined subgroups of CRC patients with significantly 
different risks of disease progression, improving the so-called biologic specificity [40] of CTC detection. 
Our findings indicate a high sensitivity and specificity for AGR2/LGR5 qRT-PCR for the surrogate 
detection of CTC in PB samples and it could be useful as a prognostic factor in patients with CRC. 
However, taking into account the design and sample size of the study, the outcome results could only 
be  considered  as  generating  a  hypothesis.  Additional  possible  limitations  of  this  study  must  be 
considered. Although the inclusion of patients with different stages and residual tumor status could be 
considered  limitations  of  the  study,  we  suggest  that  this  pragmatic  design  accurately  reflects  the 
patients  attending  the  oncology  clinic  every  day.  Thus,  the  diagnostic  performance  of  mRNA Int. J. Mol. Sci. 2012, 13  4381 
 
 
quantification has been estimated in a cohort of patients truly representative of those found in the 
clinical setting. However, to adequately assess the prognostic role, if any, of AGR2 and LGR5 mRNA 
levels in the blood, a larger, more homogeneous cohort of patients is clearly needed. Furthermore, a 
comparative study with immunofluorescence-based methods such as the Cell Search System is warranted.  
3. Experimental Section 
3.1. Patients  
Consecutive patients with CRC from the Medical Oncology Unit at the University Hospital in La 
Coruñ a (Galicia, Spain) were included in the study. Inclusion criteria were as follows: A confirmed 
pathological  diagnosis  of  colorectal  adenocarcinoma;  stage  I–III  patients  with  no  prior  systemic 
therapy for cancer; or stage IV patients without previous systemic therapy or with confirmed cancer 
progression  after  such  treatment.  Exclusion  criteria  were  defined  as  follows:  Any  other  previous 
malignancy; coagulations disorders; platelet count less than 20.0 ×  10
9 L
−1.  
The diagnostic work-up included a clinical examination, blood sampling with CA 19.9 and CEA 
serum  determination,  endoscopy  (when  clinically  indicated),  thoracic  radiograph  and  computed 
tomography (CT) scanning of the abdomen and pelvis. Chest CT was performed in patients with rectal 
tumors and stage IV patients. Patients were followed up with imaging every 8 to 12 weeks to monitor 
disease progression. 
Serum CEA (with an upper limit of normal of 5 ng/mL) and CA 19.9 (with an upper limit of normal 
of 37 U/mL) levels were determined using enzyme immunoassay (Advia Centaur, Siemens Healthcare 
Diagnostics) according to the manufacturer‘s instructions. 
PBs for qRT-PCR analyses were obtained after surgery, before neo-adjuvant chemotherapy or in 
the presence of active, clinically and radiological advanced progressive disease. At least the first 5 mL 
of blood obtained was discarded to avoid contamination with epidermal cells. 
Controls were consecutively recruited from the patients‘ family and relatives. We only excluded 
controls with a previous history of malignant disease. Thus, controls with different chronic but stable 
diseases  (e.g.,  hypertension,  diabetes  mellitus  or  heart  disease)  were  eligible  and  consecutively 
recruited. Controls were selected to include a sex and age distribution that was comparable to the 
patient group.  
This study was approved by the Ethics Committee of Clinical Investigation of Galicia (Spain), and 
written informed consents were obtained from all patients and controls prior to their inclusion in the study. 
3.2. Pathological Analysis  
Tumors and regional lymph nodes collected during surgery were processed on a routine diagnostic 
basis.  Histological  tumor  type,  depth  of  invasion  and  nodal  involvement  were  analyzed,  and  the 
disease was staged and graded according to the TNM [41].  
Residual disease status at the time of blood sampling was classified as R0 when no residual disease 
was present after surgery, R1 when microscopic residual disease was found, and R2 in the presence of 
macroscopic disease. Patients from whom the blood was obtained before the start of neo-adjuvant 
treatment were categorized as R2. Int. J. Mol. Sci. 2012, 13  4382 
 
 
3.3. Processing of Blood Samples and mRNA Isolation 
Peripheral venous blood (10 mL) was collected in EDTA-containing tubes. Samples were stabilized 
within 1 h after withdrawal in guanidinium-based RNA/DNA reagent (Roche, Germany) at 10% (v/v) 
without  cell  and  plasma  separation.  An  isolation  reagent  for  blood  and  bone  marrow  
(Roche,  Germany)  was  used  for  mRNA  extraction  according  to  the  manufacturer‘s  protocol  with 
minor modifications [10]. Purified poly(A) + RNA was further processed for qRT-PCR or stored at 
−80 ° C until use.  
The RNA concentration was determined based on UV absorption at 260 nm. The A260/A280 ratio 
was calculated to assess RNA quality and purity.  
3.4. Reverse Transcription and Quantitative Real-Time PCR  
Reverse transcription (RT) was performed on 0.02 µg of mRNA using the Superscript First-Strand 
Synthesis System (Invitrogen Life Technologies, Carlsbad, CA, USA) as described previously [10]. 
Real-time  PCR  analysis  was  performed  using  the  following  primers:  AGR2-2F, 
CTGGCCAGAGATACCACAGTC;  AGR2-2R,  AGTTGGTCACCCCAACCTC;  LGR5-F, 
CAGCGTCTTCACCTCCTAC;  LGR5-R,  TTTCCCGCAAGACGTAACTC.  The  AGR2  and  LGR5 
primers amplified 101 bp and 108 bp of the respective cDNAs. Primer pairs were chosen so that the 
sequences  were  located  in  different  exons.  Hypoxanthine-guanine  phosphoribosyl-transferase  1 
(HPRT1) was selected as reference gene, as previously reported [8]. HPRT1 (102 bp) was also used as 
an internal control to verify the RNA integrity and the efficacy of reverse transcription. Any specimen 
with inadequate HPRT1 mRNA was excluded from the study.  
The PCR reaction consisted of 10 µL of 2×  SYBR Green I Master Mix (Roche, Germany), 1.4 µL 
of forward (F) and reverse (R) primers at 5 μmol/L (Tib MolBiol, Germany), 4 µL of cDNA and  
PCR-grade  water  up  to  a  final  volume  of  20  µL  following  the  manufacturer‘s  recommendations. 
Amplifications were performed in a Light Cycler 480 (Roche Applied Science, Penzberg, Germany).  
The maximum number of cycles was 50. If after 40 cycles no fluorescent signal was detected on the 
amplification plots, the marker mRNA was assumed to be absent from the sample. 
We verified that the amplifications and the size of each PCR product were specific by melting curve 
analysis. Data analysis was performed with Light Cycler 480 Relative Quantification software (Roche 
Applied Science, Penzberg, Germany). Relative levels of expression were calculated by the 2
−Ct 
method [42]. Each assay was done at least in triplicate. The average value of the replicates was used as 
the quantitative value for each sample.  
Each  assay  included  marker-positive,  marker-negative  and  no-template  controls.  RNA  analyses 
were performed with no knowledge about clinical or follow-up data. 
3.5. Study Design and Statistical Analysis  
This project was designed as a prospective early-phase, diagnostic case-control study. The primary 
aim  was  to  estimate  the  diagnostic  performances  of  AGR2  and  LGR5  in  blood  as  clinical  
biomarkers  [43].  Receiver  operating  characteristic  (ROC)  curves  were  constructed  by  plotting 
sensitivity (y-axis) versus 1-specificity (false-positive rate; x-axis), and the area under the curve (AUC) Int. J. Mol. Sci. 2012, 13  4383 
 
 
was calculated. The optimal cutoff for mRNAs expression level that separates cancer patients and 
controls was obtained at the point of the maximum Youden index. Binary logistic regression analyses 
were used to assess for diagnostic suitability of marker combinations. 
Secondary aims included the evaluation of AGR2 and LGR5 mRNA blood levels in CRC patients 
according to the disease characteristics and clinical outcomes. Parametric tests were used to analyze 
the potential correlation between mRNA biomarker expression and clinical and pathological features 
of study subjects.  
PFS was measured as the time between the baseline PB sampling for biomarkers analysis and the 
documentation of the first tumor progression based on clinical and radiological findings or death of 
any cause. OS was defined as the time from baseline blood sampling to death of any cause. Patients 
who were alive and progression-free at the time of analysis were censored by using the time between 
the baseline PB sampling and their most recent follow-up evaluation. The Kaplan-Meier method was 
used to estimate PFS and OS. Log-rank tests were used to assess the difference between the survival 
curves. Hazard ratios (HR) were modeled using Cox proportional hazard regression analysis. 
All  statistical  tests  were  two-sided,  with  alpha  levels  lower  than  0.05  considered  statistically 
significant. PASW Statistics 18.0 for Windows (version 18.0; IBM Corporation: Armonk, NY, USA, 
2010) was used for statistical analysis. 
The  study  design  and  results  are  presented  in  accordance  with  the  REMARK  [44]  and  MIQE 
guidelines [45]. 
4. Conclusions  
Our findings indicate that the quantitative molecular assessment of AGR2 and LGR5 can serve as a 
surrogate marker of CTC and ISC-like circulating tumor cells in CRC patients. Elevated AGR2 and 
LGR5 mRNA levels in the blood are associated with poor outcome in patients with CRC.  
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